<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000778</url>
  </required_header>
  <id_info>
    <org_study_id>DATRI 008</org_study_id>
    <nct_id>NCT00000778</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin</brief_title>
  <official_title>A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the methodology for rapidly determining the early bactericidal activity (EBA),&#xD;
      tolerance, and pharmacokinetics of isoniazid and levofloxacin in the treatment of pulmonary&#xD;
      tuberculosis (TB).&#xD;
&#xD;
      Traditionally, in trials for treatment of TB, a new drug is administered in combination with&#xD;
      two or more other antituberculous agents of known effectiveness over a long period of time.&#xD;
      In this setting, it is difficult to determine the effect of any single drug or dose level.&#xD;
      Development of new agents for the treatment of TB may be accelerated by a methodology in&#xD;
      which a new agent could be evaluated for activity by administering it as a single agent over&#xD;
      a short time period. This study utilizes a method to measure the amount of bacteria present&#xD;
      each day in the lungs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally, in trials for treatment of TB, a new drug is administered in combination with&#xD;
      two or more other antituberculous agents of known effectiveness over a long period of time.&#xD;
      In this setting, it is difficult to determine the effect of any single drug or dose level.&#xD;
      Development of new agents for the treatment of TB may be accelerated by a methodology in&#xD;
      which a new agent could be evaluated for activity by administering it as a single agent over&#xD;
      a short time period. This study utilizes a method to measure the amount of bacteria present&#xD;
      each day in the lungs.&#xD;
&#xD;
      An initial cohort of patients receive isoniazid (with pyridoxine) daily for 5 days. Sputum&#xD;
      samples are collected daily for determination of the EBA (decline in colony-forming units/ml&#xD;
      sputum). If the methodology is validated, additional patients are randomized to receive one&#xD;
      of two doses of levofloxacin daily for 5 days, with determination of EBA. All patients are&#xD;
      hospitalized for 2 days of baseline evaluation and 5 days of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>44</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed in all patients:&#xD;
&#xD;
          -  Antacids if administered more than 2 hours before or after study drug.&#xD;
&#xD;
        Allowed in isoniazid patients:&#xD;
&#xD;
          -  Anticonvulsant therapy if blood levels are monitored.&#xD;
&#xD;
        Allowed in levofloxacin patients:&#xD;
&#xD;
          -  Acceptable medications other than antacids if administered at least 2 hours before or&#xD;
             1 hour after study drug.&#xD;
&#xD;
          -  Anticonvulsant therapy, theophylline, or warfarin if doses are monitored.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Presumptive active pulmonary TB.&#xD;
&#xD;
          -  No clinical evidence of central nervous system or miliary tuberculosis.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Both HIV-positive and HIV-negative patients are eligible.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Pregnant women may be enrolled in the isoniazid cohort only.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active or suspected MAI infection.&#xD;
&#xD;
          -  Active or suspected hepatitis.&#xD;
&#xD;
          -  Any other serious acute infection, diabetes, chronic obstructive pulmonary disease,&#xD;
             malignancy requiring chemotherapy, or major organ dysfunction.&#xD;
&#xD;
          -  Extreme illness or toxic appearance.&#xD;
&#xD;
          -  Pregnancy (if entering the levofloxacin portion of the study).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  All standard TB therapies.&#xD;
&#xD;
          -  Clofazimine.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Quinolones.&#xD;
&#xD;
          -  Aminoglycosides.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Pentoxifylline.&#xD;
&#xD;
          -  Colony-stimulating factors.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Interleukins.&#xD;
&#xD;
          -  Disulfiram (patients receiving isoniazid).&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of treatment-limiting intolerance or known hypersensitivity to isoniazid (in&#xD;
             patients receiving isoniazid) or to quinolones (in patients receiving levofloxacin).&#xD;
&#xD;
          -  Vomiting or diarrhea &gt;= grade 2 at screening or within 2 days prior to screening.&#xD;
&#xD;
          -  History of drug-resistant TB (in patients receiving isoniazid).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any prior treatment or prophylaxis for TB if enrolling on the isoniazid cohort.&#xD;
&#xD;
          -  Any anti-TB drug within the past 12 weeks, including standard drugs against TB as well&#xD;
             as clofazimine, rifabutin, and all quinolones and aminoglycosides.&#xD;
&#xD;
          -  Corticosteroids, pentoxifylline, colony-stimulating factors, interferons, or&#xD;
             interleukins within the past 12 weeks.&#xD;
&#xD;
        Known risk factors for multi-drug resistant (MDR) TB, including:&#xD;
&#xD;
          -  Domicile, shelter, or prison exposure to a known case of MDR TB within the past 6&#xD;
             months.&#xD;
&#xD;
          -  Residence in a specific domicile, shelter, or prison cell block within 6 months of a&#xD;
             known outbreak of MDR TB.&#xD;
&#xD;
          -  Hospitalization, within the past 6 months, on a medical service or unit in which&#xD;
             nosocomial transmission of MDR TB is known to have occurred.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hafner R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Cohn J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Egorin M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>352336505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900951793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor - UCLA Med Ctr</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Gen Med Ctr</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami / Jackson Memorial Hosp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>701122699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Southwestern Med Ctr of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine / Houston Veterans Adm Med Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>El-Sadr WM, Perlman DC, Matts JP, Nelson E, Cohn D, Telzak E, Chirgwin K, Salomon N, Olibrice M, Hafner R. Outcome of an induction regimen for the treatment of HIV-related tuberculosis (TB): evaluation of the addition of a quinolone. Int Conf AIDS. 1996 Jul 7-12;11(1):327 (abstract no TuB2358)</citation>
  </reference>
  <verification_date>June 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 6, 2008</last_update_submitted>
  <last_update_submitted_qc>August 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <keyword>Isoniazid</keyword>
  <keyword>Tuberculosis, Pulmonary</keyword>
  <keyword>Pyridoxine</keyword>
  <keyword>Ofloxacin</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Sputum</keyword>
  <keyword>Colony Count, Microbial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

